Expedia vs Tango Therapeutics Which Is More Lucrative?

Expedia Group and Tango Therapeutics are both publicly traded companies in the stock market. Expedia is a leading online travel agency, offering a wide range of travel services including booking flights, hotels, and vacation packages. Tango Therapeutics, on the other hand, is a biotechnology company focused on developing innovative cancer therapies. Both companies have seen fluctuations in their stock prices in response to various market factors and company performance. Investors may consider factors such as industry trends, financial performance, and growth prospects when evaluating these stocks for investment opportunities.

Expedia or Tango Therapeutics?

When comparing Expedia and Tango Therapeutics, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between Expedia and Tango Therapeutics.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. Expedia has a dividend yield of -%, while Tango Therapeutics has a dividend yield of -%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. Expedia reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%. On the other hand, Tango Therapeutics reports a 5-year dividend growth of 0.00% year and a payout ratio of 0.00%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with Expedia P/E ratio at 22.42 and Tango Therapeutics's P/E ratio at -2.97. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. Expedia P/B ratio is 18.09 while Tango Therapeutics's P/B ratio is 1.60.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, Expedia has seen a 5-year revenue growth of 0.18%, while Tango Therapeutics's is -0.86%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with Expedia's ROE at 92.08% and Tango Therapeutics's ROE at -49.64%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $180.02 for Expedia and $2.70 for Tango Therapeutics. Over the past year, Expedia's prices ranged from $107.25 to $190.40, with a yearly change of 77.53%. Tango Therapeutics's prices fluctuated between $2.70 and $13.01, with a yearly change of 381.67%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.